Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Meheco Group CoSHSE:600056 -0.85%67 EV-to-EBITDA is 16.97 as of Aug. 26, 2026, which is 23% above its 10-year median of 13.84. GuruFocus rates SHSE:600056 with a GF Score™ of 67/100 and a GF Value™ of ¥10.46 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 99 Medical Distribution companies, China Meheco Group Co ranks worse than 79.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China Meheco Group Co's enterprise value is ¥19,664 Mil.
China Meheco Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1,158 Mil. Therefore, China Meheco Group Co's EV-to-EBITDA for today is 16.97.
The historical rank and industry rank for China Meheco Group Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600056'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1 Med: 13.84 Max: 34.14
Current: 16.97
During the past 13 years, the highest EV-to-EBITDA of China Meheco Group Co was 34.14. The lowest was 5.10. And the median was 13.84.
SHSE:600056's EV-to-EBITDA is ranked worse than 79.8% of 99
companies
in the Medical Distribution industry
Industry Median: 8.59
vs SHSE:600056: 16.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
China Meheco Group Co (SHSE:600056) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Meheco Group Co's PE Ratio (TTM) for today is calculated as:
China Meheco Group Co's share price for today is ¥9.33.
China Meheco Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.287.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
China Meheco Group Co EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for China Meheco Group Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600056 vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, China Meheco Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Meheco Group Co EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Meheco Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Meheco Group Co's EV-to-EBITDA falls into.
China Meheco Group Co's current Enterprise Value is ¥19,664 Mil.
China Meheco Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,158 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Meheco Group Co (SHSE:600056) has a EV-to-EBITDA of 16.97 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Meheco Group Co. This is 23% above median its historical median of 13.84. Over the past decade, China Meheco Group Co's EV-to-EBITDA has ranged from 5.10 to 34.14. According to the industry distribution chart, China Meheco Group Co ranks #79 out of 99 companies in the Medical Distribution industry, placing it in the top 79.8%.
Is China Meheco Group Co's EV-to-EBITDA too high?
China Meheco Group Co's current EV-to-EBITDA of 16.97 is 23% above median its 10-year median of 13.84. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 34.14. The Medical Distribution industry median EV-to-EBITDA is 8.59. China Meheco Group Co's value of 16.97 is 97.6% above this industry median. Based on the distribution chart, China Meheco Group Co ranks #79 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China Meheco Group Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Meheco Group Co's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Meheco Group Co ranks #79 out of 99 companies for EV-to-EBITDA. This places China Meheco Group Co in the lower half of its industry. The industry median EV-to-EBITDA is 8.59. China Meheco Group Co's value of 16.97 is 97.6% above this benchmark. Historically, China Meheco Group Co's own EV-to-EBITDA has ranged from 5.10 to 34.14 over the past decade. While the company's 10-year median is 13.84 vs. the industry median of 8.59, China Meheco Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.59, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Meheco Group Co's current EV-to-EBITDA of 16.97 is 97.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Meheco Group Co. For the Medical Distribution industry, the median EV-to-EBITDA is 8.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Meheco Group Co's current EV-to-EBITDA is 16.97, which is 23% above median its own 10-year median of 13.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Meheco Group Co stock overvalued right now?
Based on GuruFocus' analysis, China Meheco Group Co (SHSE:600056) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.46, compared to a current price of ¥9.33 — trading 10.8% below its estimated fair value. The current EV-to-EBITDA is 16.97, which is 23% above median its 10-year median of 13.84 and 97.6% above the Medical Distribution industry median of 8.59. China Meheco Group Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For China Meheco Group Co (SHSE:600056), the current EV-to-EBITDA is 16.97 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Meheco Group Co (SHSE:600056) Overvalued in 2026?
Based on GuruFocus' analysis, China Meheco Group Co stock appears to be undervalued.
The current stock price of ¥9.33 is trading 10.8% below its estimated GF Value™ of ¥10.46.
GuruFocus considers China Meheco Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600056:
EV-to-EBITDA: 16.97 (23% above median its 10-year median of 13.84)
GF Value™: ¥10.46 vs. price of ¥9.33 (10.8% below fair value)
Industry Position: 97.6% above the Medical Distribution median (#79 of 99)
No single metric tells the full story. See the SHSE:600056 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Meheco Group Co Ltd is engaged in the distribution and trading of botanical medicines, medical instruments, and pharmaceuticals. It offers botanic medicines and herbal products, as well as exports of natural medicines, including herbs, spices, plant extracts, bee products, and Chinese traditional medicines. The company's business scope covers the whole industry chain, from research and development, cultivation and processing, manufacturing, distribution, and logistics to international trading, academic promotion, and technical service. The corporation provides trading services for customers in the pharmaceutical and chemical field, covering APIs, preparations, biologicals, blood products, and others.
67GF Score
Get the complete analysis for SHSE:600056
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600056 has been successfully added to your 
